Literature DB >> 2553291

Characterization of A1 adenosine receptors in atrial and ventricular myocardium from diseased human hearts.

M Böhm1, B Pieske, M Ungerer, E Erdmann.   

Abstract

The purpose of the present study was to characterize adenosine receptors in human atrial and ventricular myocardium. In isolated electrically driven preparations, adenosine produced "direct" negative inotropic effects in atrial myocardium (AT). In ventricular myocardium (VE), it only had negative inotropic properties when force of contraction had been stimulated with isoprenaline ("indirect" effect), but it has no inotropic effect alone. The adenosine receptor antagonist 8-phenyltheophylline antagonized the "direct" and "indirect" effects; these findings indicated that both effects were mediated by adenosine receptors. In cardiac membranes from human AT and VE, adenosine receptors were characterized with [3H]-8-cyclopentyl-1,3-dipropylxanthine (DPCPX) binding. The effects of agonists R-(-)-N6-phenylisopropyladenosine (R-PIA), S-(+)-N6-phenylisopropyladenosine (S-PIA), and 5'-(N-ethylcarboxamido) adenosine (NECA) and the effects of guanine nucleotides [Gpp(NH)p] were studied also. The antagonist affinities as judged from the apparent affinity, Kd, of [3H]DPCPX were similar in AT (2.2 nmol/l; 95% confidence limits, 1.4-3.7) and VE (1.8 nmol/l; 95% confidence limits, 1.0-3.0). The number of adenosine receptors was 1.7 times greater in AT (26.9 +/- 2.33 fmol/mg protein; n = 5) than in VE (16.2 +/- 2.3 fmol/mg protein; n = 5). High and low affinity states of adenosine receptors evaluated with the influence of Gpp(NH)p on agonist competition with R-PIA were similar in AT or VE. The rank orders of potency for agonists (R-PIA greater than S-PIA greater than NECA) and antagonists (DPCPX greater than 8-phenyltheophylline greater than theophylline) were characteristic for the A1 receptor subtype. It is concluded that A1 adenosine receptors exist in the human myocardium. Since binding properties were similar in AT and VE, the same A1 adenosine receptor probably couples to different effectors in a similar guanine nucleotide-dependent way. [3H]DPCPX is the first radiolabeled antagonist ligand that allows detection of A1 adenosine receptors and their coupling in the human myocardium.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553291     DOI: 10.1161/01.res.65.5.1201

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  18 in total

1.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

2.  Adenosine receptors involved in the inhibitory control of non-adrenergic non-cholinergic neurotransmission in guinea-pig atria belong to the A1 subtype.

Authors:  A Rubino; S Amerini; L Mantelli; F Ledda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

3.  Measurement of adenylate cyclase activity in the right ventricular endomyocardial biopsy samples from patients with chronic congestive heart failure.

Authors:  A Sugiyama; T Shirai; K Inoue; K G Lurie; K Hashimoto
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.

Authors:  M Ungerer; M Böhm; R H Schwinger; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

5.  Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

Authors:  M Böhm; C Weinhold; R H Schwinger; J Müller-Ehmsen; D Böhm; H Reichenspurner; B Reichart; E Erdmann
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Characterization of adenosine receptors in intact cultured heart cells.

Authors:  D el-Ani; K A Jacobson; A Shainberg
Journal:  Biochem Pharmacol       Date:  1994-08-17       Impact factor: 5.858

7.  Adenosine receptors and nucleoside transport sites in cardiac cells.

Authors:  F E Parkinson; A S Clanachan
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

8.  Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients.

Authors:  Rebekka V Jensen; Natasha E Zachara; Per H Nielsen; Hans Henrik Kimose; Steen B Kristiansen; Hans Erik Bøtker
Journal:  Cardiovasc Res       Date:  2012-12-01       Impact factor: 10.787

9.  A positive inotropic effect of adenosine in cardiac preparations of right atria from diseased human hearts.

Authors:  Ulrich Gergs; Peter Boknik; Wilhelm Schmitz; Andreas Simm; Rolf-Edgar Silber; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-11-27       Impact factor: 3.000

Review 10.  [Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for the therapy with inotropic drugs].

Authors:  M Böhm; R H Schwinger; E Erdmann
Journal:  Klin Wochenschr       Date:  1990-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.